immune response biopharma Latest News

Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision

Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

Immune Response BioPharma, Inc. Sets Pricing of REMUNE Vaccine in Thailand Between $75-100 Per Dose for Emergency Approval of HIV/AIDS Vaccine

Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.

Immune Response BioPharma, Inc. Selects the American Stock Transfer & Trust Company as Transfer Agent of Record.

Immune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Results

Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS

Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision

Immune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group.

Immune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and a Partnership by the end of Q1 2013

REMUNE Effectiveness Extends Years After Inoculation REMUNE Injected Patient Has 2 Healthy HIV Free Children Proving the Vaccine has Strong Immune Responses a Decade Later

Immune Response BioPharma, Inc. Sees First Year REMUNE Sales North of $1 Billion Dollars

Immune Response BioPharma, Inc. Review of Blockbuster RA Vaccine RAVAX Phase 2B 340 Patient Study Results Demonstrated a 50% Improvement in Patients Vaccinated with RAVAX.

Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

Immune Response BioPharma, Inc. Posts 1st Half 2012 Results Highlights include IRBP Granted U.S. Patent 8,053,197 for Auto-Immune Diseases & Plans for a Phase 2B NeuroVax Study and a Phase 3 RAVAX Study for RA.

Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK

Immune Response BioPharma, Inc. announced today that it has received United States Patent Number 8,053,197 expanding coverage relating to its immune-based therapy for Treatment of Auto-Immune Diseases.